FDAnews
www.fdanews.com/articles/206102-fda-shortens-booster-interval-for-moderna-covid-19-shot-to-five-months

FDA Shortens Booster Interval for Moderna COVID-19 Shot to Five Months

January 10, 2022

The FDA has reduced the time required to receive a Moderna COVID-19 booster shot for people 18 years old and up from six months to five, following a primary series vaccination.

The decision came shortly after the agency updated the Emergency Use Authorization for Pfizer/BioNTech’s booster, shortening the time between completion of a primary vaccination series to five months for individuals aged 12 and older.

Citing the rapid increase in infections from the highly contagious Omicron variant, Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, urged all vaccinated individuals to get a booster jab.

View today's stories